The company has decided to delay its SG299 therapy for patients with blood cancer. As of June 30 Sana had a cash position of 3259 million, down from 434 million at the end of December. With the layoffs announced Tuesday the company expects its cash burn rate to be below 200 million next year. Sana is certainly not alone in shedding staff amid a downturn in biotech financing